

Congenital Hyperinsulinism Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/C22C0ABEC2D8EN.html>

Date: January 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: C22C0ABEC2D8EN

Abstracts

Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

This report contains market size and forecasts of Congenital Hyperinsulinism in Global, including the following market information:

Global Congenital Hyperinsulinism Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Congenital Hyperinsulinism market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Surgery Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Congenital Hyperinsulinism include IVAX Pharmaceuticals, Teva Pharmaceuticals, Zealand Pharma, Rezolute, Xeris Pharmaceuticals, Eiger BioPharmaceuticals, AmideBio and Recordati, etc. In 2021, the

global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Hyperinsulinism companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Hyperinsulinism Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, by Type, 2021 (%)

Surgery

Medication

Others

Global Congenital Hyperinsulinism Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Congenital Hyperinsulinism Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Congenital Hyperinsulinism Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Congenital Hyperinsulinism revenues in global market, 2017-2022
(estimated), (\$ millions)

Key companies Congenital Hyperinsulinism revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

IVAX Pharmaceuticals

Teva Pharmaceuticals

Zealand Pharma

Rezolute

Xeris Pharmaceuticals

Eiger BioPharmaceuticals

AmideBio

Recordati

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Congenital Hyperinsulinism Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Congenital Hyperinsulinism Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL CONGENITAL HYPERINSULINISM OVERALL MARKET SIZE

- 2.1 Global Congenital Hyperinsulinism Market Size: 2021 VS 2028
- 2.2 Global Congenital Hyperinsulinism Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Congenital Hyperinsulinism Players in Global Market
- 3.2 Top Global Congenital Hyperinsulinism Companies Ranked by Revenue
- 3.3 Global Congenital Hyperinsulinism Revenue by Companies
- 3.4 Top 3 and Top 5 Congenital Hyperinsulinism Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Congenital Hyperinsulinism Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Congenital Hyperinsulinism Players in Global Market
 - 3.6.1 List of Global Tier 1 Congenital Hyperinsulinism Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Congenital Hyperinsulinism Market Size Markets, 2021 & 2028

4.1.2 Surgery

4.1.3 Medication

4.1.4 Others

4.2 By Type - Global Congenital Hyperinsulinism Revenue & Forecasts

4.2.1 By Type - Global Congenital Hyperinsulinism Revenue, 2017-2022

4.2.2 By Type - Global Congenital Hyperinsulinism Revenue, 2023-2028

4.2.3 By Type - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Congenital Hyperinsulinism Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Congenital Hyperinsulinism Revenue & Forecasts

5.2.1 By Application - Global Congenital Hyperinsulinism Revenue, 2017-2022

5.2.2 By Application - Global Congenital Hyperinsulinism Revenue, 2023-2028

5.2.3 By Application - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Congenital Hyperinsulinism Market Size, 2021 & 2028

6.2 By Region - Global Congenital Hyperinsulinism Revenue & Forecasts

6.2.1 By Region - Global Congenital Hyperinsulinism Revenue, 2017-2022

6.2.2 By Region - Global Congenital Hyperinsulinism Revenue, 2023-2028

6.2.3 By Region - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Congenital Hyperinsulinism Revenue, 2017-2028

6.3.2 US Congenital Hyperinsulinism Market Size, 2017-2028

6.3.3 Canada Congenital Hyperinsulinism Market Size, 2017-2028

6.3.4 Mexico Congenital Hyperinsulinism Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Congenital Hyperinsulinism Revenue, 2017-2028

6.4.2 Germany Congenital Hyperinsulinism Market Size, 2017-2028

6.4.3 France Congenital Hyperinsulinism Market Size, 2017-2028

6.4.4 U.K. Congenital Hyperinsulinism Market Size, 2017-2028

6.4.5 Italy Congenital Hyperinsulinism Market Size, 2017-2028

6.4.6 Russia Congenital Hyperinsulinism Market Size, 2017-2028

6.4.7 Nordic Countries Congenital Hyperinsulinism Market Size, 2017-2028

6.4.8 Benelux Congenital Hyperinsulinism Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Congenital Hyperinsulinism Revenue, 2017-2028

6.5.2 China Congenital Hyperinsulinism Market Size, 2017-2028

6.5.3 Japan Congenital Hyperinsulinism Market Size, 2017-2028

6.5.4 South Korea Congenital Hyperinsulinism Market Size, 2017-2028

6.5.5 Southeast Asia Congenital Hyperinsulinism Market Size, 2017-2028

6.5.6 India Congenital Hyperinsulinism Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Congenital Hyperinsulinism Revenue, 2017-2028

6.6.2 Brazil Congenital Hyperinsulinism Market Size, 2017-2028

6.6.3 Argentina Congenital Hyperinsulinism Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Congenital Hyperinsulinism Revenue, 2017-2028

6.7.2 Turkey Congenital Hyperinsulinism Market Size, 2017-2028

6.7.3 Israel Congenital Hyperinsulinism Market Size, 2017-2028

6.7.4 Saudi Arabia Congenital Hyperinsulinism Market Size, 2017-2028

6.7.5 UAE Congenital Hyperinsulinism Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 IVAX Pharmaceuticals

7.1.1 IVAX Pharmaceuticals Corporate Summary

7.1.2 IVAX Pharmaceuticals Business Overview

7.1.3 IVAX Pharmaceuticals Congenital Hyperinsulinism Major Product Offerings

7.1.4 IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue in Global Market (2017-2022)

7.1.5 IVAX Pharmaceuticals Key News

7.2 Teva Pharmaceuticals

7.2.1 Teva Pharmaceuticals Corporate Summary

7.2.2 Teva Pharmaceuticals Business Overview

7.2.3 Teva Pharmaceuticals Congenital Hyperinsulinism Major Product Offerings

7.2.4 Teva Pharmaceuticals Congenital Hyperinsulinism Revenue in Global Market

(2017-2022)

7.2.5 Teva Pharmaceuticals Key News

7.3 Zealand Pharma

7.3.1 Zealand Pharma Corporate Summary

7.3.2 Zealand Pharma Business Overview

7.3.3 Zealand Pharma Congenital Hyperinsulinism Major Product Offerings

7.3.4 Zealand Pharma Congenital Hyperinsulinism Revenue in Global Market

(2017-2022)

7.3.5 Zealand Pharma Key News

7.4 Rezolute

7.4.1 Rezolute Corporate Summary

7.4.2 Rezolute Business Overview

7.4.3 Rezolute Congenital Hyperinsulinism Major Product Offerings

7.4.4 Rezolute Congenital Hyperinsulinism Revenue in Global Market (2017-2022)

7.4.5 Rezolute Key News

7.5 Xeris Pharmaceuticals

7.5.1 Xeris Pharmaceuticals Corporate Summary

7.5.2 Xeris Pharmaceuticals Business Overview

7.5.3 Xeris Pharmaceuticals Congenital Hyperinsulinism Major Product Offerings

7.5.4 Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue in Global Market

(2017-2022)

7.5.5 Xeris Pharmaceuticals Key News

7.6 Eiger BioPharmaceuticals

7.6.1 Eiger BioPharmaceuticals Corporate Summary

7.6.2 Eiger BioPharmaceuticals Business Overview

7.6.3 Eiger BioPharmaceuticals Congenital Hyperinsulinism Major Product Offerings

7.6.4 Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue in Global Market

(2017-2022)

7.6.5 Eiger BioPharmaceuticals Key News

7.7 AmideBio

7.7.1 AmideBio Corporate Summary

7.7.2 AmideBio Business Overview

7.7.3 AmideBio Congenital Hyperinsulinism Major Product Offerings

7.7.4 AmideBio Congenital Hyperinsulinism Revenue in Global Market (2017-2022)

7.7.5 AmideBio Key News

7.8 Recordati

7.8.1 Recordati Corporate Summary

7.8.2 Recordati Business Overview

7.8.3 Recordati Congenital Hyperinsulinism Major Product Offerings

7.8.4 Recordati Congenital Hyperinsulinism Revenue in Global Market (2017-2022)

7.8.5 Recordati Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Congenital Hyperinsulinism Market Opportunities & Trends in Global Market

Table 2. Congenital Hyperinsulinism Market Drivers in Global Market

Table 3. Congenital Hyperinsulinism Market Restraints in Global Market

Table 4. Key Players of Congenital Hyperinsulinism in Global Market

Table 5. Top Congenital Hyperinsulinism Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Congenital Hyperinsulinism Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Congenital Hyperinsulinism Revenue Share by Companies, 2017-2022

Table 8. Global Companies Congenital Hyperinsulinism Product Type

Table 9. List of Global Tier 1 Congenital Hyperinsulinism Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Congenital Hyperinsulinism Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Congenital Hyperinsulinism Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Congenital Hyperinsulinism Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Congenital Hyperinsulinism Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Congenital Hyperinsulinism Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Congenital Hyperinsulinism Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Congenital Hyperinsulinism Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Congenital Hyperinsulinism Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Congenital Hyperinsulinism Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Congenital Hyperinsulinism Revenue, (US\$, Mn),

2023-2028

Table 22. By Country - Europe Congenital Hyperinsulinism Revenue, (US\$, Mn),
2017-2022

Table 23. By Country - Europe Congenital Hyperinsulinism Revenue, (US\$, Mn),
2023-2028

Table 24. By Region - Asia Congenital Hyperinsulinism Revenue, (US\$, Mn),
2017-2022

Table 25. By Region - Asia Congenital Hyperinsulinism Revenue, (US\$, Mn),
2023-2028

Table 26. By Country - South America Congenital Hyperinsulinism Revenue, (US\$, Mn),
2017-2022

Table 27. By Country - South America Congenital Hyperinsulinism Revenue, (US\$, Mn),
2023-2028

Table 28. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue,
(US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue,
(US\$, Mn), 2023-2028

Table 30. IVAX Pharmaceuticals Corporate Summary

Table 31. IVAX Pharmaceuticals Congenital Hyperinsulinism Product Offerings

Table 32. IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue (US\$, Mn),
(2017-2022)

Table 33. Teva Pharmaceuticals Corporate Summary

Table 34. Teva Pharmaceuticals Congenital Hyperinsulinism Product Offerings

Table 35. Teva Pharmaceuticals Congenital Hyperinsulinism Revenue (US\$, Mn),
(2017-2022)

Table 36. Zealand Pharma Corporate Summary

Table 37. Zealand Pharma Congenital Hyperinsulinism Product Offerings

Table 38. Zealand Pharma Congenital Hyperinsulinism Revenue (US\$, Mn),
(2017-2022)

Table 39. Rezolute Corporate Summary

Table 40. Rezolute Congenital Hyperinsulinism Product Offerings

Table 41. Rezolute Congenital Hyperinsulinism Revenue (US\$, Mn), (2017-2022)

Table 42. Xeris Pharmaceuticals Corporate Summary

Table 43. Xeris Pharmaceuticals Congenital Hyperinsulinism Product Offerings

Table 44. Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue (US\$, Mn),
(2017-2022)

Table 45. Eiger BioPharmaceuticals Corporate Summary

Table 46. Eiger BioPharmaceuticals Congenital Hyperinsulinism Product Offerings

Table 47. Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue (US\$, Mn),

(2017-2022)

Table 48. AmideBio Corporate Summary

Table 49. AmideBio Congenital Hyperinsulinism Product Offerings

Table 50. AmideBio Congenital Hyperinsulinism Revenue (US\$, Mn), (2017-2022)

Table 51. Recordati Corporate Summary

Table 52. Recordati Congenital Hyperinsulinism Product Offerings

Table 53. Recordati Congenital Hyperinsulinism Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Congenital Hyperinsulinism Segment by Type in 2021

Figure 2. Congenital Hyperinsulinism Segment by Application in 2021

Figure 3. Global Congenital Hyperinsulinism Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Congenital Hyperinsulinism Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Congenital Hyperinsulinism Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Congenital Hyperinsulinism Revenue in 2021

Figure 8. By Type - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

Figure 9. By Application - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

Figure 10. By Region - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

Figure 11. By Country - North America Congenital Hyperinsulinism Revenue Market Share, 2017-2028

Figure 12. US Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Congenital Hyperinsulinism Revenue Market Share, 2017-2028

Figure 16. Germany Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 17. France Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Congenital Hyperinsulinism Revenue Market Share, 2017-2028

Figure 24. China Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028

- Figure 28. India Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Congenital Hyperinsulinism Revenue Market Share, 2017-2028
- Figure 30. Brazil Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 32. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue Market Share, 2017-2028
- Figure 33. Turkey Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 34. Israel Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 35. Saudi Arabia Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 36. UAE Congenital Hyperinsulinism Revenue, (US\$, Mn), 2017-2028
- Figure 37. IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 38. Teva Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 39. Zealand Pharma Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 40. Rezolute Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 41. Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 42. Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 43. AmideBio Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 44. Recordati Congenital Hyperinsulinism Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Congenital Hyperinsulinism Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/C22C0ABEC2D8EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C22C0ABEC2D8EN.html>